Pancreatic Cancer and Carbon Ion Radiotherapy

Last updated: February 18, 2025
Sponsor: University Hospital Heidelberg
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Pancreatitis

Pancreatic Disorders

Pancreatic Cancer

Treatment

Carbon Ion

Clinical Study ID

NCT04194268
RADONK-PACK-2019
  • Ages > 18
  • All Genders

Study Summary

Irradiation of non-operable pancreatic cancer with carbon ions (C12). This therapy is expected to be more effective than the current Gold Standard of photon irradiation applied in the case of non-operable pancreatic cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically confirmed, inoperable primary or local recurrent pancreatic cancer

  • Written informed consent (must be available before enrollment in the trial)

  • Karnofsky performance score > 60 or ECOG-status 0/1 (at least: patient should beable to take care of himself, although daily-life activity or work is not possible)

  • Age ≥ 18 years

Exclusion

Exclusion Criteria:

  • No clear difference between tumor edge and upper gastrointestinal tract in baselineimaging

  • Extensive lymphatic metastases

  • Disability of subject to understand character and individual consequences of theclinical trial

  • Distant metastases

  • Previous radiotherapy of the upper abdomen

  • Active medical implants (e.g. pacemaker, defibrillator), contradicting radiotherapyat HIT

  • Participation in another clinical study or observation period of competing trials,respectively

Study Design

Total Participants: 25
Treatment Group(s): 1
Primary Treatment: Carbon Ion
Phase:
Study Start date:
December 03, 2019
Estimated Completion Date:
December 09, 2025

Connect with a study center

  • University Hopsital Heidelberg

    Heidelberg, 69120
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.